Kidney transplant breakthrough? drug combo aims to reduce lifelong pills
NCT ID NCT04803006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called siplizumab combined with donor bone marrow cells to help kidney transplant patients potentially stop taking anti-rejection drugs long-term. Only 4 people took part before the study was ended early. The goal was to find the best dose to safely allow the body to accept the new kidney without needing lifelong medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant